{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:23:53Z","timestamp":1791343433524,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/tpj.2016.67","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T10:40:55Z","timestamp":1474972855000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes"],"prefix":"10.1038","volume":"18","author":[{"given":"S-W","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C W","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T A","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E R","family":"Gamazon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-9784","authenticated-orcid":false,"given":"T","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Cooper-DeHoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"BFtpj201667_CR1","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/circ.131.suppl_2.o29","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association. Circulation 2015; 131: e29\u2013322.","journal-title":"Circulation"},{"key":"BFtpj201667_CR2","unstructured":"WHO Global Status Report on Noncommunicable Diseases 2014. World Health Organization: Switzerland, 2014."},{"key":"BFtpj201667_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jdiacomp.2008.04.002","volume":"23","author":"D Weycker","year":"2009","unstructured":"Weycker D, Nichols GA, O'Keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM et al. Excess risk of diabetes in persons with hypertension. J Diabetes Complicat 2009; 23: 330\u2013336.","journal-title":"J Diabetes Complicat"},{"key":"BFtpj201667_CR4","doi-asserted-by":"crossref","unstructured":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"BFtpj201667_CR5","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2337\/dc07-1768","volume":"31","author":"AK Gupta","year":"2008","unstructured":"Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR . Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014blood pressure lowering arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982\u2013988.","journal-title":"Diabetes Care"},{"key":"BFtpj201667_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.amjcard.2006.04.030","volume":"98","author":"R Cooper-Dehoff","year":"2006","unstructured":"Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890\u2013894.","journal-title":"Am J Cardiol"},{"key":"BFtpj201667_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BFtpj201667_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201\u2013207.","journal-title":"Lancet"},{"key":"BFtpj201667_CR9","doi-asserted-by":"publisher","first-page":"f6745","DOI":"10.1136\/bmj.f6745","volume":"347","author":"L Shen","year":"2013","unstructured":"Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 2013; 347: f6745.","journal-title":"BMJ"},{"key":"BFtpj201667_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4330\/wjc.v6.i7.517","volume":"6","author":"CV Rizos","year":"2014","unstructured":"Rizos CV, Elisaf MS . Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6: 517\u2013530.","journal-title":"World J Cardiol"},{"key":"BFtpj201667_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"JI Barzilay","year":"2006","unstructured":"Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191\u20132201.","journal-title":"Arch Intern Med"},{"key":"BFtpj201667_CR12","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","volume":"43","author":"P Verdecchia","year":"2004","unstructured":"Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963\u2013969.","journal-title":"Hypertension"},{"key":"BFtpj201667_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/HJH.0b013e328122dd58","volume":"25","author":"T Almgren","year":"2007","unstructured":"Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK . Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311\u20131317.","journal-title":"J Hypertens"},{"key":"BFtpj201667_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","volume":"95","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR . Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29\u201335.","journal-title":"Am J Cardiol"},{"key":"BFtpj201667_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1161\/HYPERTENSIONAHA.106.085654","volume":"50","author":"TA Aksnes","year":"2007","unstructured":"Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S . Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467\u2013473.","journal-title":"Hypertension"},{"key":"BFtpj201667_CR16","first-page":"195","volume":"51","author":"A Karagiannis","year":"2010","unstructured":"Karagiannis A, Tziomalos K, Pagourelias ED, Gossios TD, Athyros VG . Effect of antihypertensive drug-associated diabetes on cardiovascular risk. Hellenic J Cardiol 2010; 51: 195\u2013199.","journal-title":"Hellenic J Cardiol"},{"key":"BFtpj201667_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/jhh.2008.41","volume":"22","author":"TA Aksnes","year":"2008","unstructured":"Aksnes TA, Kjeldsen SE, Rostrup M, Storset O, Hua TA, Julius S . Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens 2008; 22: 520\u2013527.","journal-title":"J Hum Hypertens"},{"key":"BFtpj201667_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1749-6632.2010.05838.x","volume":"1212","author":"LK Billings","year":"2010","unstructured":"Billings LK, Florez JC . The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 2010; 1212: 59\u201377.","journal-title":"Ann N Y Acad Sci"},{"key":"BFtpj201667_CR19","doi-asserted-by":"publisher","first-page":"e1000932","DOI":"10.1371\/journal.pgen.1000932","volume":"6","author":"H Zhong","year":"2010","unstructured":"Zhong H, Beaulaurier J, Lum PY, Molony C, Yang X, Macneil DJ et al. Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. PLoS Genet 2010; 6: e1000932.","journal-title":"PLoS Genet"},{"key":"BFtpj201667_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/FPC.0000000000000012","volume":"23","author":"JH Karnes","year":"2013","unstructured":"Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langaee TY et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genomics 2013; 23: 697\u2013705.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201667_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/tpj.2012.34","volume":"13","author":"JH Karnes","year":"2013","unstructured":"Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J 2013; 13: 430\u2013436.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201667_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/FPC.0b013e32810f2e3c","volume":"17","author":"AL Beitelshees","year":"2007","unstructured":"Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR\/Trandolapril STudy (INVEST). Pharmacogenet Genomics 2007; 17: 719\u2013729.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201667_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0735-1097(98)00423-9","volume":"32","author":"CJ Pepine","year":"1998","unstructured":"Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P et al. Rationale and design of the International Verapamil SR\/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32: 1228\u20131237.","journal-title":"J Am Coll Cardiol"},{"key":"BFtpj201667_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559\u2013575.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201667_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"L Alkes","year":"2006","unstructured":"Alkes L, Price NJP, Plenge Robert M, Weinblatt Michael E, Shadick Nancy A, Reich David . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904\u2013909.","journal-title":"Nat Genet"},{"key":"BFtpj201667_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nmeth.1785","volume":"9","author":"O Delaneau","year":"2012","unstructured":"Delaneau O, Marchini J, Zagury JF . A linear complexity phasing method for thousands of genomes. Nat Methods 2012; 9: 179\u2013181.","journal-title":"Nat Methods"},{"key":"BFtpj201667_CR27","doi-asserted-by":"publisher","first-page":"e1000529","DOI":"10.1371\/journal.pgen.1000529","volume":"5","author":"BN Howie","year":"2009","unstructured":"Howie BN, Donnelly P, Marchini J . A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.","journal-title":"PLoS Genet"},{"key":"BFtpj201667_CR28","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","volume":"26","author":"CJ Willer","year":"2010","unstructured":"Willer CJ, Li Y, Abecasis GR . METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26: 2190\u20132191.","journal-title":"Bioinformatics"},{"key":"BFtpj201667_CR29","doi-asserted-by":"publisher","first-page":"e1000888","DOI":"10.1371\/journal.pgen.1000888","volume":"6","author":"DL Nicolae","year":"2010","unstructured":"Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ . Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010; 6: e1000888.","journal-title":"PLoS Genet"},{"key":"BFtpj201667_CR30","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1073\/pnas.1001827107","volume":"107","author":"ER Gamazon","year":"2010","unstructured":"Gamazon ER, Huang RS, Cox NJ, Dolan ME . Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci USA 2010; 107: 9287\u20139292.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201667_CR31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"Human genomics","year":"2015","unstructured":"Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015; 348: 648\u2013660.","journal-title":"Science"},{"key":"BFtpj201667_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S et al. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580\u2013585.","journal-title":"Nat Genet"},{"key":"BFtpj201667_CR33","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1001\/jama.290.14.1884","volume":"290","author":"KM Narayan","year":"2003","unstructured":"Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF . Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884\u20131890.","journal-title":"JAMA"},{"key":"BFtpj201667_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1592\/phco.24.16.1529.50952","volume":"24","author":"JC Barner","year":"2004","unstructured":"Barner JC, Worchel J, Yang M . Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy 2004; 24: 1529\u20131538.","journal-title":"Pharmacotherapy"},{"key":"BFtpj201667_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/ki.2012.252","volume":"82","author":"L Perisic","year":"2012","unstructured":"Perisic L, Lal M, Hulkko J, Hultenby K, Onfelt B, Sun Y et al. Plekhh2, a novel podocyte protein downregulated in human focal segmental glomerulosclerosis, is involved in matrix adhesion and actin dynamics. Kidney Int 2012; 82: 1071\u20131083.","journal-title":"Kidney Int"},{"key":"BFtpj201667_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00439-008-0548-y","volume":"124","author":"CN Greene","year":"2008","unstructured":"Greene CN, Keong LM, Cordovado SK, Mueller PW . Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. Hum Genet 2008; 124: 255\u2013262.","journal-title":"Hum Genet"},{"key":"BFtpj201667_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ng.120","volume":"40","author":"E Zeggini","year":"2008","unstructured":"Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638\u2013645.","journal-title":"Nat Genet"},{"key":"BFtpj201667_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng.732","volume":"43","author":"ZJ Chen","year":"2011","unstructured":"Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Li Z et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43: 55\u201359.","journal-title":"Nat Genet"},{"key":"BFtpj201667_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jmedgenet-2011-100427","volume":"49","author":"MO Goodarzi","year":"2012","unstructured":"Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen YD et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49: 90\u201395.","journal-title":"J Med Genet"},{"key":"BFtpj201667_CR40","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ng.450","volume":"41","author":"RA Eeles","year":"2009","unstructured":"Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116\u20131121.","journal-title":"Nat Genet"},{"key":"BFtpj201667_CR41","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1038\/sj.onc.1206867","volume":"22","author":"V Rippe","year":"2003","unstructured":"Rippe V, Drieschner N, Meiboom M, Murua Escobar H, Bonk U, Belge G et al. Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 2003; 22: 6111\u20136114.","journal-title":"Oncogene"},{"key":"BFtpj201667_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2337\/db09-1048","volume":"59","author":"AM Simonis-Bik","year":"2010","unstructured":"Simonis-Bik AM, Nijpels G, van Haeften TW, Houwing-Duistermaat JJ, Boomsma DI, Reiling E et al. Gene variants in the novel type 2 diabetes loci CDC123\/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 2010; 59: 293\u2013301.","journal-title":"Diabetes"},{"key":"BFtpj201667_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ctrv.2015.04.004","volume":"41","author":"M Santoni","year":"2015","unstructured":"Santoni M, Andrikou K, Sotte V, Bittoni A, Lanese A, Pellei C et al. Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. Cancer Treat Rev 2015; 41: 569\u2013576.","journal-title":"Cancer Treat Rev"},{"key":"BFtpj201667_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE . Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98\u2013107.","journal-title":"Nat Rev Immunol"},{"key":"BFtpj201667_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/icb.2014.4","volume":"92","author":"C Westwell-Roper","year":"2014","unstructured":"Westwell-Roper C, Nackiewicz D, Dan M, Ehses JA . Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunol Cell Biol 2014; 92: 314\u2013323.","journal-title":"Immunol Cell Biol"},{"key":"BFtpj201667_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","volume":"4","author":"RW Grant","year":"2013","unstructured":"Grant RW, Dixit VD . Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol 2013; 4: 50.","journal-title":"Front Immunol"},{"key":"BFtpj201667_CR47","doi-asserted-by":"publisher","first-page":"13924","DOI":"10.1073\/pnas.1402665111","volume":"111","author":"J Fadista","year":"2014","unstructured":"Fadista J, Vikman P, Laakso EO, Mollet IG, Esguerra JL, Taneera J et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc Natl Acad Sci USA 2014; 111: 13924\u201313929.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201667_CR48","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00125-011-2188-3","volume":"54","author":"JE Below","year":"2011","unstructured":"Below JE, Gamazon ER, Morrison JV, Konkashbaev A, Pluzhnikov A, McKeigue PM et al. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 2011; 54: 2047\u20132055.","journal-title":"Diabetologia"},{"key":"BFtpj201667_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ajhg.2012.08.002","volume":"91","author":"SC Elbein","year":"2012","unstructured":"Elbein SC, Gamazon ER, Das SK, Rasouli N, Kern PA, Cox NJ . Genetic risk factors for type 2 diabetes: a trans-regulatory genetic architecture? Am J Hum Genet 2012; 91: 466\u2013477.","journal-title":"Am J Hum Genet"},{"key":"BFtpj201667_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4239\/wjd.v5.i2.97","volume":"5","author":"SK Das","year":"2014","unstructured":"Das SK, Sharma NK . Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility. World J Diabetes 2014; 5: 97\u2013114.","journal-title":"World J Diabetes"},{"key":"BFtpj201667_CR51","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215\u20132222.","journal-title":"Lancet"},{"key":"BFtpj201667_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/pedi.12015","volume":"14","author":"JM Torres","year":"2013","unstructured":"Torres JM, Cox NJ, Philipson LH . Genome wide association studies for diabetes: perspective on results and challenges. Pediatr Diabetes 2013; 14: 90\u201396.","journal-title":"Pediatr Diabetes"},{"key":"BFtpj201667_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/genes6010087","volume":"6","author":"RB Prasad","year":"2015","unstructured":"Prasad RB, Groop L . Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 2015; 6: 87\u2013123.","journal-title":"Genes (Basel)"},{"key":"BFtpj201667_CR54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/tpj.2015.47","volume":"16","author":"JC Maranville","year":"2015","unstructured":"Maranville JC, Cox NJ . Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. Pharmacogenomics J 2015; 16: 388\u2013392.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201667_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849\u2013857.","journal-title":"JAMA"},{"key":"BFtpj201667_CR56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1161\/CIRCGENETICS.110.957654","volume":"3","author":"Y Niu","year":"2010","unstructured":"Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 2010; 3: 548\u2013555.","journal-title":"Circ Cardiovasc Genet"},{"key":"BFtpj201667_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.111.00823","volume":"62","author":"CW McDonough","year":"2013","unstructured":"McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O et al. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension 2013; 62: 48\u201354.","journal-title":"Hypertension"},{"key":"BFtpj201667_CR58","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","volume":"115","author":"NA Limdi","year":"2010","unstructured":"Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827\u20133834.","journal-title":"Blood"},{"key":"BFtpj201667_CR59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.thromres.2011.04.010","volume":"128","author":"T Yin","year":"2011","unstructured":"Yin T, Miyata T . Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 2011; 128: 307\u2013316.","journal-title":"Thromb Res"},{"key":"BFtpj201667_CR60","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/bioinformatics\/btq419","volume":"26","author":"RJ Pruim","year":"2010","unstructured":"Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336\u20132337.","journal-title":"Bioinformatics"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tpj201667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201667","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/tpj.2016.67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/tpj201667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:47:41Z","timestamp":1684622861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFtpj201667"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2016.67","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]},"assertion":[{"value":"14 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CWM, YG, MAP, JAJ, CJP and RMC-D have received support from NIH. CJP, JAJ and RMC-D also received support for this project from Abbott Laboratories. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}